New hope for bone marrow failure: drug calms immune attack

NCT ID NCT05998408

Recruiting now Disease control Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 21, 2026 · Updated 18 times

Summary

This study tests a pill called ruxolitinib for adults whose immune system attacks their bone marrow, causing conditions like severe anemia. The drug aims to calm the immune attack and improve blood cell counts. Participants take the pill twice daily for up to 6 months and are monitored closely with blood tests and bone marrow biopsies. The goal is to see if the drug is safe and effective in controlling the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE APLASTIC ANEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HYPOPLASTIC MDS SEVERE APLASTIC ANEMIA SINGLE LINEAGE CYTOPENIAS, T-LGL